查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584135

神经内分泌肿瘤治疗市场，按治疗类型、药物类别、肿瘤类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Neuroendocrine Tumor Treatment Market, By Therapy Type, By Drug Class, By Tumor Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年神经内分泌肿瘤治疗市场规模为25.1021亿美元，2024年至2032年复合年增长率为9.10%。

神经内分泌肿瘤治疗市场-市场动态

越来越多的临床试验加速了神经内分泌肿瘤治疗市场的创新

越来越多的临床试验正在显着加速神经内分泌肿瘤（NET）治疗市场的创新，反映出人们越来越重视开发标靶疗法。例如，2021 年，美国国立卫生研究院 (NIH) 报告了超过 350 项专门针对 NET 的活跃临床试验，凸显了探索新治疗途径的紧迫性。诺华 (Novartis) 和易普森 (Ipsen) 等製药公司在临床研究上投入巨资，以评估新型药物，包括生长抑素类似物和胜肽受体放射性核素疗法 (PRRT)。此外，欧洲神经内分泌肿瘤协会 (ENETS) 等倡议在促进合作研究工作、促进治疗方案的更快进展方面发挥了重要作用。因此，这些努力预计将产生有前景的新疗法，并提高神经内分泌肿瘤患者的治疗效果和生活品质。

神经内分泌肿瘤治疗市场-关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 9.10% 左右的复合年增长率成长

根据治疗类型细分，生长抑素模拟疗法预计将在 2023 年显示最大的市场份额

根据药物类别细分，生长抑素类似物是2023年的主导类型

根据肿瘤类型细分，胃肠胰神经内分泌肿瘤（GEP-NETs）是 2023 年的主要类型

按地区划分，北美是 2023 年的主要收入来源

神经内分泌肿瘤治疗市场-細項分析：

全球神经内分泌肿瘤治疗市场根据治疗类型、药物类别、肿瘤类型、最终用户和地区进行细分。

根据治疗类型，市场分为四类：生长抑素类似疗法、胜肽受体放射性核素治疗（PRRT）、标靶治疗和化疗。生长抑素类似疗法因其在症状管理方面的既定功效而处于领先地位。紧随其后的是胜肽受体放射性核素疗法（PRRT），它获得了标靶治疗的牵引力。标靶治疗和化疗也很重要，儘管优先顺序较低。

根据药物类别，市场分为四类：生长抑素类似物、酪胺酸激酶抑制剂、mTOR 抑制剂和烷基化剂。生长抑素类似物因其在控制症状和肿瘤生长方面的有效性而具有最高优先顺序。随后是酪胺酸激酶抑制剂，提供针对性的作用。 mTOR 抑制剂和烷基化剂也很重要，但优先顺序较低。

神经内分泌肿瘤治疗市场-地理洞察

神经内分泌肿瘤（NET）治疗市场在盛行率、治疗选择和研究活动方面表现出显着的地理差异。在先进的医疗基础设施和对肿瘤学研究的大量投资的推动下，北美脱颖而出，成为领先地区，根据美国癌症协会的数据，美国每年报告约 12,000 例新的 NET 病例。欧洲也发挥着至关重要的作用，特别是在德国和英国等国家，欧洲神经内分泌肿瘤协会(ENETS) 等倡议促进研究人员和临床医生之间的合作，以加强治疗方案和治疗的可及性。在亚太地区，中国和印度等新兴市场对神经内分泌肿瘤的认识和诊断率不断提高，促使医疗保健提供者扩大治疗选择。此外，日本神经内分泌肿瘤学会等组织正在努力提高对 NET 的理解和管理，从而促进市场占有率的成长。因此，这些地理见解显示了一个动态的景观，具有不同程度的治疗进展和研究重点。

神经内分泌肿瘤治疗市场-竞争格局：

神经内分泌肿瘤（NET）治疗市场的竞争格局特征是参与者多元化，包括製药巨头和专业生物技术公司。诺华（Novartis）和益普生（Ipsen）等领先机构处于领先地位，其药物（包括善宁（Sandostatin）和索马图林（Somatuline））在对症治疗和肿瘤控制市场占据主导地位。 2023 年，诺华报告善宁的销售额超过 20 亿美元，凸显了其庞大的市场份额。 Advanced Accelerator Applications（诺华子公司）和 Clovis Oncology 等新兴企业正在创新疗法方面取得长足进步，包括放射性配体治疗和标靶治疗，这些疗法在临床环境中越来越受到关注。合作和策略伙伴关係也很普遍，拜耳和辉瑞等公司寻求透过收购和合併来增强其产品组合，特别是拜耳收购了用于靶向放射性核素治疗的镥 Lu 177 的权利。此外，对研究和开发的关注仍然很高，大量临床试验探索新的治疗方式，反映出旨在改善 NET 治疗患者预后的充满活力和竞争的环境。

最新进展：

2024 年 1 月，FDA 批准 Lu 177-dotatate (Lutathera) 作为晚期神经内分泌肿瘤的初始治疗药物，与奥曲肽联合使用可显着改善无进展生存期和肿瘤缩小，从而增加了患者的治疗选择。

2024 年 3 月，FDA 授予 AlphaMedix (212Pb-DOTAMTATE) 突破性疗法认定，用于治疗晚期胃肠胰腺神经内分泌肿瘤。这标誌着一项重大进步，因为它是第一个获得这一地位的标靶阿尔法疗法，从而加速了其发展。

目录

第一章：神经内分泌肿瘤治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按治疗类型分類的神经内分泌肿瘤治疗市场片段
    • 按药物类别分類的神经内分泌肿瘤治疗市场片段
    • 按肿瘤类型分類的神经内分泌肿瘤治疗市场片段
    • 最终使用者的神经内分泌肿瘤治疗市场片段
    • 按国家/地区分類的神经内分泌肿瘤治疗市场片段
    • 按地区分類的神经内分泌肿瘤治疗市场片段
  • 竞争洞察

第 3 章：神经内分泌肿瘤治疗主要市场趋势

  • 神经内分泌肿瘤治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 神经内分泌肿瘤治疗市场限制
    • 市场限制影响分析
  • 神经内分泌肿瘤治疗市场机会
  • 神经内分泌肿瘤治疗市场未来趋势

第 4 章：神经内分泌肿瘤治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：神经内分泌肿瘤治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：神经内分泌肿瘤治疗市场格局

  • 2023 年神经内分泌肿瘤治疗市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：神经内分泌肿瘤治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 生长抑素类似疗法
    • 胜肽受体放射性核种治疗 (PRRT)
    • 标靶治疗
    • 化疗

第 8 章：神经内分泌肿瘤治疗市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 生长抑素类似物
    • 酪胺酸激酶抑制剂
    • mTOR抑制剂
    • 烷基化剂

第 9 章：神经内分泌肿瘤治疗市场 - 按肿瘤类型

  • 概述
    • 按肿瘤类型分類的细分市场份额分析
    • 胃肠胰神经内分泌肿瘤 (GEP-NET)
    • 肺神经内分泌肿瘤
    • 其他的

第 10 章：神经内分泌肿瘤治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 癌症专科诊所
    • 研究所

第 11 章：神经内分泌肿瘤治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经内分泌肿瘤治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按肿瘤类型）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经内分泌肿瘤治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按肿瘤类型）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区神经内分泌肿瘤治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依肿瘤类型）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲神经内分泌肿瘤治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按肿瘤类型）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲神经内分泌肿瘤治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模和预测（按治疗类型）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按肿瘤类型）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第12章：主要供应商分析-神经内分泌肿瘤治疗产业

  • 竞争仪表板
  • 公司简介
    • Novartis AG
    • Pfizer Inc.
    • Ipsen SA
    • Advanced Accelerator Applications SA
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Roche Holding AG
    • Bristol-Myers Squibb Company
    • Bayer AG
    • GlaxoSmithKline plc
    • Eli Lilly and Company
    • Sanofi SA
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Hutchison China MediTech Limited (Hutchmed)
    • Lexicon Pharmaceuticals, Inc.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4115

REPORT HIGHLIGHT

Neuroendocrine Tumor Treatment Market size was valued at USD 2,510.21 Million in 2023, expanding at a CAGR of 9.10% from 2024 to 2032.

The Neuroendocrine Tumor Treatment Market focuses on therapies designed to manage neuroendocrine tumors (NETs), which originate from neuroendocrine cells and can occur in various organs. With an increasing global incidence of NETs-affecting approximately 6.98 cases per 100,000 people-the demand for effective treatment options is on the rise. Rising awareness about NETs, advancements in targeted therapies, and the growing number of clinical trials contribute significantly to market growth. However, high treatment costs and a lack of knowledge among healthcare professionals can hinder market expansion. Opportunities lie in the development of novel therapeutics and combination therapies, along with the potential for personalized medicine, which could enhance treatment efficacy. As healthcare systems evolve, the integration of advanced diagnostic techniques, such as PET scans and molecular imaging, is anticipated to improve patient outcomes and drive further growth in the market.

Neuroendocrine Tumor Treatment Market- Market Dynamics

Growing Number of Clinical Trials Accelerates Innovation in the Neuroendocrine Tumor Treatment Market

The growing number of clinical trials is significantly accelerating innovation in the neuroendocrine tumor (NET) treatment market, reflecting an increasing focus on developing targeted therapies. For instance, in 2021, the National Institutes of Health (NIH) reported over 350 active clinical trials specifically for NETs, highlighting the urgency to explore new treatment avenues. Pharmaceutical companies such as Novartis and Ipsen have invested heavily in clinical research to evaluate novel agents, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Furthermore, initiatives like the European Neuroendocrine Tumor Society (ENETS) have been instrumental in promoting collaborative research efforts, enabling faster advancements in treatment protocols. As a result, these efforts are anticipated to yield promising new therapies that enhance patient outcomes and quality of life for those diagnosed with neuroendocrine tumors.

Neuroendocrine Tumor Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.10% over the forecast period (2024-2032)

Based on Therapy Type segmentation, Somatostatin Analog Therapy was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Somatostatin Analogs was the leading type in 2023

Based on Tumor Type segmentation, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) were the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroendocrine Tumor Treatment Market- Segmentation Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Therapy Type, Drug Class, Tumor Type, End-User, and Region.

The market is divided into four categories based on Therapy Type: Somatostatin Analog Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy, and Chemotherapy. Somatostatin Analog Therapy leads due to its established efficacy in symptom management. Following closely is Peptide Receptor Radionuclide Therapy (PRRT), gaining traction for targeted treatment. Targeted Therapy and Chemotherapy are also important, albeit with lower priority.

The market is divided into four categories based on Drug Class: Somatostatin Analogs, Tyrosine Kinase Inhibitors, mTOR Inhibitors, and Alkylating Agents. Somatostatin Analogs hold the highest priority due to their effectiveness in managing symptoms and tumor growth. Tyrosine Kinase Inhibitors follow, offering targeted action. mTOR Inhibitors and Alkylating Agents are also significant but with lower priority.

Neuroendocrine Tumor Treatment Market- Geographical Insights

The neuroendocrine tumor (NET) treatment market exhibits significant geographical variations in prevalence, treatment options, and research activities. North America stands out as the leading region, driven by advanced healthcare infrastructure and substantial investment in oncology research, with the U.S. reporting approximately 12,000 new NET cases annually according to the American Cancer Society. Europe also plays a crucial role, particularly in countries like Germany and the UK, where initiatives like the European Neuroendocrine Tumor Society (ENETS) foster collaboration among researchers and clinicians to enhance treatment protocols and access to therapies. In Asia-Pacific, emerging markets such as China and India are witnessing increasing awareness and diagnosis rates of neuroendocrine tumors, prompting healthcare providers to expand treatment options. Additionally, initiatives like the Japanese Society of Neuroendocrine Tumors are working to improve the understanding and management of NETs, thereby contributing to a growing market presence. As a result, these geographical insights indicate a dynamic landscape with varying levels of treatment advancements and research emphasis.

Neuroendocrine Tumor Treatment Market- Competitive Landscape:

The competitive landscape of the neuroendocrine tumor (NET) treatment market is characterized by a diverse array of players, including pharmaceutical giants and specialized biotech companies. Leading organizations such as Novartis and Ipsen are at the forefront, with their drugs, including Sandostatin and Somatuline, dominating the market for symptomatic treatment and tumor control. In 2023, Novartis reported over $2 billion in sales for Sandostatin, underscoring its significant market share. Emerging players like Advanced Accelerator Applications (a Novartis subsidiary) and Clovis Oncology are making strides with innovative therapies, including radioligand treatments and targeted therapies, which are gaining traction in clinical settings. Collaborations and strategic partnerships are also prevalent, as companies like Bayer and Pfizer seek to enhance their product portfolios through acquisitions and mergers, notably Bayer's acquisition of the rights to Lutetium Lu 177 for targeted radionuclide therapy. Furthermore, the focus on research and development remains high, with numerous clinical trials exploring novel treatment modalities, reflecting a vibrant and competitive environment aimed at improving patient outcomes in NET treatment.

Recent Developments:

In January 2024, the FDA's approval of Lu 177-dotatate (Lutathera) as an initial treatment for advanced neuroendocrine tumors, showed significant improvements in progression-free survival and tumor shrinkage when combined with octreotide, enhancing therapeutic options for patients.

In March 2024, the FDA granted breakthrough therapy designation to AlphaMedix (212Pb-DOTAMTATE) for treating advanced gastroenteropancreatic neuroendocrine tumors. This marks a significant advancement as it is the first targeted alpha therapy to receive this status, expediting its development.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Pfizer Inc.
  • Ipsen S.A.
  • Advanced Accelerator Applications S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Sanofi S.A.
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Hutchison China MediTech Limited (Hutchmed)
  • Lexicon Pharmaceuticals, Inc.
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analog Therapy
  • Peptide Receptor Radionuclide Therapy (PRRT)
  • Targeted Therapy
  • Chemotherapy

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analogs
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • Alkylating Agents

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY TUMOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Lung Neuroendocrine Tumors
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Specialty Clinics
  • Research Institutes

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroendocrine Tumor Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroendocrine Tumor Treatment Market Snippet by Therapy Type
    • 2.1.2. Neuroendocrine Tumor Treatment Market Snippet by Drug Class
    • 2.1.3. Neuroendocrine Tumor Treatment Market Snippet by Tumor Type
    • 2.1.4. Neuroendocrine Tumor Treatment Market Snippet by End-User
    • 2.1.5. Neuroendocrine Tumor Treatment Market Snippet by Country
    • 2.1.6. Neuroendocrine Tumor Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroendocrine Tumor Treatment Key Market Trends

  • 3.1. Neuroendocrine Tumor Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroendocrine Tumor Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroendocrine Tumor Treatment Market Opportunities
  • 3.4. Neuroendocrine Tumor Treatment Market Future Trends

4. Neuroendocrine Tumor Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroendocrine Tumor Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroendocrine Tumor Treatment Market Landscape

  • 6.1. Neuroendocrine Tumor Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroendocrine Tumor Treatment Market - By Therapy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 7.1.2. Somatostatin Analog Therapy
    • 7.1.3. Peptide Receptor Radionuclide Therapy (PRRT)
    • 7.1.4. Targeted Therapy
    • 7.1.5. Chemotherapy

8. Neuroendocrine Tumor Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Somatostatin Analogs
    • 8.1.3. Tyrosine Kinase Inhibitors
    • 8.1.4. mTOR Inhibitors
    • 8.1.5. Alkylating Agents

9. Neuroendocrine Tumor Treatment Market - By Tumor Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Tumor Type, 2023 & 2032 (%)
    • 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    • 9.1.3. Lung Neuroendocrine Tumors
    • 9.1.4. Others

10. Neuroendocrine Tumor Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Cancer Specialty Clinics
    • 10.1.4. Research Institutes

11. Neuroendocrine Tumor Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroendocrine Tumor Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroendocrine Tumor Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroendocrine Tumor Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Neuroendocrine Tumor Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Neuroendocrine Tumor Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroendocrine Tumor Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Novartis AG
    • 12.2.2. Pfizer Inc.
    • 12.2.3. Ipsen S.A.
    • 12.2.4. Advanced Accelerator Applications S.A.
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. AstraZeneca PLC
    • 12.2.7. Roche Holding AG
    • 12.2.8. Bristol-Myers Squibb Company
    • 12.2.9. Bayer AG
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Eli Lilly and Company
    • 12.2.12. Sanofi S.A.
    • 12.2.13. Boehringer Ingelheim GmbH
    • 12.2.14. Teva Pharmaceutical Industries Ltd.
    • 12.2.15. Hutchison China MediTech Limited (Hutchmed)
    • 12.2.16. Lexicon Pharmaceuticals, Inc.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us